Cargando…
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era
OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Ef...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/ https://www.ncbi.nlm.nih.gov/pubmed/34253248 http://dx.doi.org/10.1186/s12967-021-02975-3 |
_version_ | 1783721486161281024 |
---|---|
author | Botticelli, Andrea Pomati, Giulia Cirillo, Alessio Mammone, Giulia Ciurluini, Fabio Cerbelli, Bruna Sciattella, Paolo Ralli, Massimo Romeo, Umberto De Felice, Francesca Catalano, Carlo Vullo, Francesco Della Monaca, Marco Amirhassankhani, Sasan Tomao, Silverio Valentini, Valentino De Vincentiis, Marco Tombolini, Vincenzo Della Rocca, Carlo Polimeni, Antonella di Gioia, Cira Corsi, Alessandro D’Amati, Giulia Mezi, Silvia Marchetti, Paolo |
author_facet | Botticelli, Andrea Pomati, Giulia Cirillo, Alessio Mammone, Giulia Ciurluini, Fabio Cerbelli, Bruna Sciattella, Paolo Ralli, Massimo Romeo, Umberto De Felice, Francesca Catalano, Carlo Vullo, Francesco Della Monaca, Marco Amirhassankhani, Sasan Tomao, Silverio Valentini, Valentino De Vincentiis, Marco Tombolini, Vincenzo Della Rocca, Carlo Polimeni, Antonella di Gioia, Cira Corsi, Alessandro D’Amati, Giulia Mezi, Silvia Marchetti, Paolo |
author_sort | Botticelli, Andrea |
collection | PubMed |
description | OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach. METHODS: A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in a first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities were analysed. RESULTS: Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients in weekly group (21) were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35% (36 patients) and 34% (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%). CONCLUSION: The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed. |
format | Online Article Text |
id | pubmed-8274020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82740202021-07-13 Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era Botticelli, Andrea Pomati, Giulia Cirillo, Alessio Mammone, Giulia Ciurluini, Fabio Cerbelli, Bruna Sciattella, Paolo Ralli, Massimo Romeo, Umberto De Felice, Francesca Catalano, Carlo Vullo, Francesco Della Monaca, Marco Amirhassankhani, Sasan Tomao, Silverio Valentini, Valentino De Vincentiis, Marco Tombolini, Vincenzo Della Rocca, Carlo Polimeni, Antonella di Gioia, Cira Corsi, Alessandro D’Amati, Giulia Mezi, Silvia Marchetti, Paolo J Transl Med Research OBJECTIVE: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach. METHODS: A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in a first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities were analysed. RESULTS: Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients in weekly group (21) were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35% (36 patients) and 34% (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%). CONCLUSION: The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed. BioMed Central 2021-07-12 /pmc/articles/PMC8274020/ /pubmed/34253248 http://dx.doi.org/10.1186/s12967-021-02975-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Botticelli, Andrea Pomati, Giulia Cirillo, Alessio Mammone, Giulia Ciurluini, Fabio Cerbelli, Bruna Sciattella, Paolo Ralli, Massimo Romeo, Umberto De Felice, Francesca Catalano, Carlo Vullo, Francesco Della Monaca, Marco Amirhassankhani, Sasan Tomao, Silverio Valentini, Valentino De Vincentiis, Marco Tombolini, Vincenzo Della Rocca, Carlo Polimeni, Antonella di Gioia, Cira Corsi, Alessandro D’Amati, Giulia Mezi, Silvia Marchetti, Paolo Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title_full | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title_fullStr | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title_full_unstemmed | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title_short | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
title_sort | weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274020/ https://www.ncbi.nlm.nih.gov/pubmed/34253248 http://dx.doi.org/10.1186/s12967-021-02975-3 |
work_keys_str_mv | AT botticelliandrea weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT pomatigiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT cirilloalessio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT mammonegiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT ciurluinifabio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT cerbellibruna weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT sciattellapaolo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT rallimassimo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT romeoumberto weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT defelicefrancesca weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT catalanocarlo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT vullofrancesco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT dellamonacamarco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT amirhassankhanisasan weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT tomaosilverio weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT valentinivalentino weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT devincentiismarco weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT tombolinivincenzo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT dellaroccacarlo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT polimeniantonella weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT digioiacira weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT corsialessandro weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT damatigiulia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT mezisilvia weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera AT marchettipaolo weeklychemotherapyasfirstlinetreatmentinfrailheadandneckcancerpatientsintheimmunotherapyera |